 |
市場調查報告書
商品編碼
1373891
全球腎臟生物標記市場規模、佔有率和成長分析：按類型和最終用戶 - 行業預測（2023-2030）Global Renal Biomakers Market Size, Share, Growth Analysis, By Type(Functional biomarkers, up-regulated proteins), By End-user(Hospitals, diagnostic laboratories) - Industry Forecast 2023-2030 |
||||||
2021年全球腎臟生物標記市場規模為11.2億美元，從2022年的12億美元增加到2030年的21.6億美元，年複合成長率預計將成長7.6%。
由於對腎臟疾病的高效診斷工具和個體化治療方法的需求不斷成長，該市場正在呈現顯著成長。市場成長是由多種因素驅動的。首先，全球腎臟疾病盛行率的不斷上升推動了對準確、可靠的診斷工具的需求。由於高齡化、糖尿病和高血壓負擔的增加以及生活方式相關因素等因素，慢性腎臟病尤其顯著。及時診斷和管理腎臟疾病的需要導致臨床實踐中擴大採用腎臟生物標記。此外，技術進步和創新生物標記檢測技術的發展提高了腎臟生物標記檢測的敏感度、特異性和準確性。這些進步使醫療保健專業人員能夠做出更資訊的治療決策並有效監測腎臟疾病的進展。此外，對個人化醫療和標靶治療的重視增加了對可以預測治療反應並指導選擇適當治療性介入的生物標記的需求。
全球腎臟生物標記市場動態
全球腎臟生物標記市場的促進因素
腎臟疾病盛行率增加
慢性腎臟病（CKD）、腎衰竭和急性腎損傷（AKI）等腎臟疾病的發生率和盛行率不斷增加，推動了對腎臟生物標記的需求。這些生物標記在腎臟疾病的早期檢測、準確診斷和監測中發揮重要作用，從而能夠及時干涉並改善患者的預後。
診斷技術的進步
蛋白質體學、基因組學和代謝組學等診斷技術的進步擴大了可用腎臟生物標記的範圍。這些技術提高了檢測腎功能障礙和評估疾病進展的敏感性、特異性和準確性。將這些技術與傳統診斷方法整合進一步增加了對腎臟生物標記的需求。
全球腎臟生物標記市場的抑制因素
法規挑戰
生物標記的法規形勢複雜且不斷變化。獲得法規的核准並滿足嚴格的品質和安全標準需要時間和資源。與生物標記開發和商業化相關的法規挑戰可能會阻礙市場成長和創新。
認知和採用有限
儘管腎臟生物標記具有潛在的好處，但醫療保健專業人員和患者對生物標記在腎臟疾病管理中的效用的認知仍然有限。缺乏對腎臟生物標記的效用和益處的教育和認知可能會阻礙普及和利用。
全球腎臟生物標記的趨勢
擴大採用個人化醫療：腎臟生物標記領域的個人化醫療呈現成長趨勢。醫療保健提供者擴大利用生物標記根據患者個體特徵和疾病進展制定治療計劃。這種方法可以實現更有針對性和更有效的治療，進而改善患者的治療效果。
生物標記發現技術的進步：生物標記發現領域取得了重大進展，特別是在基因組學、蛋白質組學和代謝組學領域。這些技術的進步將能夠識別與腎臟疾病相關的新的、更特異性的生物標記。組學技術與先進分析和機器學習技術的整合進一步增強了生物標記發現的能力。
本報告研究和分析了全球腎臟生物標記市場，提供市場動態和前景、細分分析、公司簡介等。
目錄
執行摘要
調查方法
母市場分析
主要市場考察
- 技術分析
- 價格分析
- 供應鏈分析
- 價值鏈分析
- 市場生態系統
- 智慧財產權分析
- 貿易分析
- 啟動分析
- 原料分析
- 創新矩陣
- 研發線產品分析
- 總體經濟指標
- 主要投資分析
- 關鍵成功因素
- 競爭程度
市場動態及展望
- 市場動態
- 促進因素
- 機會
- 抑制因素
- 任務
- 法規形勢
- 波特的分析
- 對未來中斷的特殊考察
全球腎臟生物標記市場：按類型
- 市場概況
- 功能性生物標記
- 上調蛋白質
- 其他生物標記類型
全球腎臟生物標記市場：依最終用戶分類
- 市場概況
- 醫院
- 診斷實驗室
- 其他最終用戶
全球腎臟生物標記市場規模：按地區分類
- 市場概況
- 北美洲
- 美國
- 加拿大
- 歐洲
- 德國
- 西班牙
- 法國
- 英國
- 歐洲其他地區
- 亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
- 拉丁美洲
- 巴西
- 其他拉丁美洲
- 中東/非洲
- 海灣合作理事會國家
- 南非
- 其他中東/非洲
競爭形勢
- 前5名企業對比
- 主要企業市場定位（2021年）
- 主要市場參與者所採取的策略
- 關鍵成功策略
- 近期市集活動
- 主要企業市場佔有率（2021年）
主要企業簡介
- Siemens Healthineers - Germany
- Roche Diagnostics - Switzerland
- Abbott Laboratories - US
- Thermo Fisher Scientific Inc. - US
- Beckman Coulter, Inc. (Danaher Corporation) - US
- bioMerieux SA - France
- Randox Laboratories Ltd. - UK
- Ortho Clinical Diagnostics - US
- Fujirebio Inc. (Miraca Holdings Inc.) - Japan
- Bio-Rad Laboratories, Inc. - US
- Nova Biomedical Corporation - US
- Ortho Clinical Diagnostics - US
- Quest Diagnostics Incorporated - US
- Sysmex Corporation - Japan
- ACON Laboratories, Inc. - US
- Gold Standard Diagnostics Corp. - US
- R&D Systems, Inc. (Bio-Techne Corporation) - US
- Dako (Agilent Technologies, Inc.) - US
- DiaSorin SpA - Italy
- Tosoh Corporation - Japan
Global Renal Biomakers Market size was valued at USD 1.12 billion in 2021 and is poised to grow from USD 1.2 billion in 2022 to USD 2.16 billion by 2030, at a CAGR of 7.6% during the forecast period (2023-2030).
The global renal biomarkers market is experiencing significant growth as the demand for efficient diagnostic tools and personalized treatment approaches for renal diseases continues to rise. Renal biomarkers are specific indicators or substances that provide valuable information about kidney function, injury, or disease progression. These biomarkers play a crucial role in the early detection, diagnosis, and monitoring of various renal conditions, such as chronic kidney disease, acute kidney injury, and renal transplantation. The growth of the global market is driven by several factors. Firstly, the increasing prevalence of renal diseases worldwide is fueling the demand for accurate and reliable diagnostic tools. Chronic kidney disease, in particular, has witnessed a significant rise due to factors such as aging populations, the growing burden of diabetes and hypertension, and lifestyle-related factors. The need for timely diagnosis and management of renal diseases has led to the adoption of renal biomarkers in clinical settings. Moreover, advancements in technology and the development of innovative biomarker detection techniques have improved the sensitivity, specificity, and accuracy of renal biomarker tests. These advancements enable healthcare professionals to make more informed treatment decisions and monitor the progression of renal diseases effectively. Additionally, the emphasis on personalized medicine and targeted therapies is driving the demand for biomarkers that can predict treatment response and guide the selection of appropriate therapeutic interventions.
Top-down and bottom-up approaches were used to estimate and validate the size of the global Renal Biomakers Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined by using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Renal Biomakers Market Segmental Analysis
Global Renal Biomakers Market is segmented on the basis of type, end-user, and region. By type, the market is segmented into functional biomarkers, up-regulated proteins, and other biomarker types. By end user, the market is segmented into hospitals, diagnostic laboratories, and other end users. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
Global Renal Biomakers Market Dynamics
Drivers of the Global Renal Biomakers Market
Increasing Prevalence of Renal Diseases
The growing incidence and prevalence of renal diseases, including chronic kidney disease (CKD), kidney failure, and acute kidney injury (AKI), are driving the demand for renal biomarkers. These biomarkers play a crucial role in early detection, accurate diagnosis, and monitoring of renal diseases, thereby enabling timely intervention and improved patient outcomes.
Technological Advancements in Diagnostic Technologies
The advancements in diagnostic technologies, such as proteomics, genomics, and metabolomics, have expanded the range of available renal biomarkers. These technologies offer enhanced sensitivity, specificity, and accuracy in detecting renal dysfunction and evaluating disease progression. The integration of these technologies with traditional diagnostic methods has further fueled the demand for renal biomarkers.
Restraints in the Global Renal Biomakers Market
Regulatory Challenges
The regulatory landscape for biomarkers is complex and constantly evolving. Obtaining regulatory approvals and meeting stringent quality and safety standards can be time-consuming and resource-intensive. The regulatory challenges associated with biomarker development and commercialization can hinder market growth and innovation.
Limited Awareness and Adoption
Despite the potential benefits of renal biomarkers, there is still limited awareness among healthcare professionals and patients about their utility in renal disease management. Lack of education and awareness about the availability and benefits of renal biomarkers may hinder their widespread adoption and utilization in clinical practice.
Market Trends of Global Renal Biomakers Key
Increasing Adoption of Personalized Medicine: There is a growing trend towards personalized medicine in the field of renal biomarkers. Healthcare providers are increasingly utilizing biomarkers to tailor treatment plans based on individual patient characteristics and disease progression. This approach enables more targeted and effective therapies, leading to improved patient outcomes.
Advancements in Biomarker Discovery Techniques: The field of biomarker discovery is witnessing significant advancements, particularly in the areas of genomics, proteomics, and metabolomics. These technological advancements allow for the identification of novel and more specific biomarkers associated with renal diseases. The integration of omics technologies with advanced analytics and machine learning techniques is further enhancing biomarker discovery capabilities.
Table of Contents
- Executive Summary
- Market Overview
- Wheel of Fortune
- Research Methodology
- Information Procurement
- Secondary & Primary Data Sources
- Market Size Estimation
- Market Assumptions & Limitations
- Parent Market Analysis
- Market Overview
- Market Size
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
- Key Market Insights
- Technology Analysis
- Pricing Analysis
- Supply Chain Analysis
- Value Chain Analysis
- Ecosystem of the Market
- IP Analysis
- Trade Analysis
- Startup Analysis
- Raw Material Analysis
- Innovation Matrix
- Pipeline Product Analysis
- Macroeconomic Indicators
- Top Investment Analysis
- Key Success Factor
- Degree of Competition
- Market Dynamics & Outlook
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
- Regulatory Landscape
- Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
- Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
- Global Renal Biomakers Market by Type
- Market Overview
- Functional biomarkers
- up-regulated proteins
- and other biomarker types
- Global Renal Biomakers Market by End-user
- Market Overview
- Hospitals
- diagnostic laboratories
- and other end users
- Global Renal Biomakers Market Size by Region
- Market Overview
- North America
- USA
- Canada
- Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA
- Competitive Landscape
- Top 5 Player Comparison
- Market Positioning of Key Players, 2021
- Strategies Adopted by Key Market Players
- Top Winning Strategies
- By Development
- By Company
- By Year
- Recent Activities in the Market
- Key Companies Market Share (%), 2021
- Key Company Profiles
- Siemens Healthineers - Germany
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Roche Diagnostics - Switzerland
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Abbott Laboratories - US
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Thermo Fisher Scientific Inc. - US
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Beckman Coulter, Inc. (Danaher Corporation) - US
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- bioMerieux SA - France
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Randox Laboratories Ltd. - UK
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Ortho Clinical Diagnostics - US
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Fujirebio Inc. (Miraca Holdings Inc.) - Japan
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bio-Rad Laboratories, Inc. - US
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Nova Biomedical Corporation - US
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Ortho Clinical Diagnostics - US
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Quest Diagnostics Incorporated - US
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sysmex Corporation - Japan
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- ACON Laboratories, Inc. - US
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Gold Standard Diagnostics Corp. - US
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- R&D Systems, Inc. (Bio-Techne Corporation) - US
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Dako (Agilent Technologies, Inc.) - US
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- DiaSorin S.p.A. - Italy
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Tosoh Corporation - Japan
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
